Amgen Inc. (AMGN) Up 4.8% — Should I Scale Into This Winner?
Amgen Inc. (AMGN) showed strong performance in the latest session, with the stock advancing 4.84% to close at $354.98. That move represents a gain of $16.39 from the prior close at $338.59, underscoring clear bullish activity in the share price. With this surge, the stock is now trading above its recent 52-week high of $353.25 set on Jan. 27, 2026, signaling that AMGN is pushing into fresh high ground rather than merely retesting prior resistance. The step up to a new high adds to the evidence of strong upward momentum, as buyers continue to gain ground at progressively higher price levels.
Trading activity was relatively light compared with recent history, with volume of 1,117,843 shares versus a 90-day average of 2,696,173. That indicates today’s advance came on below-average turnover, suggesting the price move has been driven more by steady accumulation than by a volume spike. Even so, the size of the percentage gain and the break above the previous 52-week high highlight solid upward pressure in the name. Within the large-cap biopharmaceutical group, Amgen has outpaced many high-profile sector peers such as Eli Lilly and Company (LLY), Johnson & Johnson (JNJ), and Vertex Pharmaceuticals Incorporated (VRTX) in this session. The combination of a fresh high, a clear single-day percentage gain of 4.84% and sustained price strength positions AMGN as one of the stocks currently surging within its sector.
Why Amgen Inc. Price is Moving Higher
Amgen Inc. shares have been grinding higher as investors respond to a combination of solid fundamentals and steady, if unspectacular, sentiment from Wall Street. The stock’s recent trading in the $340–$342 range reflects resilience after previous moves from the high-$200s, supported by 12.40% revenue growth and a healthy 19.47% profit margin. Those metrics reinforce the view that Amgen is executing well in a challenging biopharmaceutical environment, helping justify its roughly $182 billion valuation. The market is rewarding this consistency: despite a slight day-to-day dip around Jan. 30, 2026, the price has held near recent monthly closes, signaling buyers are willing to step in on minor weakness.
Analyst coverage is also contributing to the positive tone. Consensus ratings skew toward “hold,” but with a constructive bias—average price targets in the low-to-mid $300s suggest modest upside from recent levels, and the upper end of the range has moved as high as the low-to-mid $400s. Earlier target increases, such as Royal Bank of Canada’s move from $235 to $280 with an “outperform” stance, helped reset expectations higher and continue to underpin confidence. Against a backdrop of strong peers in large-cap health care, Amgen’s solid earnings power—reflected in EPS of $12.94—supports the idea that it remains a durable cash generator. Together, these factors are fostering bullish sentiment and keeping momentum tilted to the upside, even in the absence of headline-grabbing catalysts or major corporate announcements.
What is the Amgen Inc. Rating - Should I Buy?
Weiss Ratings assigns AMGN a B rating. Current recommendation is Buy. This places Amgen Inc. among the stronger opportunities in the Health Care space for investors seeking a blend of quality, income and long-term growth potential. The B rating signals that, on a risk-adjusted basis, Amgen has delivered a favorable balance of performance and stability compared with many publicly traded stocks.
The rating is supported by the Excellent Growth Index and Excellent Efficiency Index. Double‑digit revenue growth of 12.40% combined with a profit margin of 19.47% shows that Amgen is expanding while maintaining attractive profitability. An exceptionally high return on equity of 81.71% aligns with the Excellent Efficiency Index, indicating that management is generating substantial earnings relative to shareholder capital. The Good Dividend Index further enhances the appeal for investors who value income along with growth.
On the risk side, Amgen earns a Good Solvency Index, indicating a solid balance sheet to support ongoing operations and research investment. Meanwhile, the Fair Total Return Index and Fair Volatility Index imply that, while performance has been constructive, price appreciation and risk levels have been closer to middle-of-the-pack than top-tier. A forward P/E of 26.17 indicates investors are willing to pay a premium for Amgen’s earnings stream, consistent with its B (Buy) rating but still requiring selectivity on entry points.
Within its sector, Amgen’s B rating is in line with large-cap peers such as Eli Lilly and Company (LLY, B), Johnson & Johnson (JNJ, B) and Gilead Sciences, Inc. (GILD, B), and slightly ahead of Vertex Pharmaceuticals Incorporated (VRTX, B-) and United Therapeutics Corporation (UTHR, B). This positions AMGN as a competitive, high-quality name in a group of generally well-regarded Health Care leaders.
About Amgen Inc.
Amgen Inc. is a leading biotechnology company focused on discovering, developing and delivering innovative human therapeutics. Operating within the global Health Care sector, Amgen specializes in biologic medicines that target serious illnesses where there is significant unmet medical need. The company’s portfolio spans oncology, hematology, cardiovascular disease, inflammation, nephrology and bone health, with a strong emphasis on complex biologic therapies and advanced modalities. Over the past decades, Amgen has built a reputation as one of the pioneers in recombinant DNA and molecular biology, translating cutting-edge science into therapies used in clinical practice worldwide.
Within the Pharmaceuticals, Biotechnology and Life Sciences industry, Amgen’s competitive strength is rooted in its deep scientific capabilities, robust pipeline and large-scale biologics manufacturing expertise. Its branded therapies are widely used in oncology and immunology, and the company has a growing presence in biosimilars, offering alternatives to established biologic treatments. Amgen also invests heavily in research platforms such as human genetics and advanced biologics engineering, which can help it identify high-value targets and develop more precise, mechanism-based therapies. This integrated approach—from discovery through commercialization—supports Amgen’s position as a major player in biotechnology therapeutics listed on the NASDAQ, with a broad, diversified portfolio of products reaching patients in many international markets.
Investor Outlook
With a Weiss Rating of B (Buy), Amgen Inc. (AMGN) appears favorably positioned for investors looking for potential for continued gains in the Health Care space. From here, watch how the stock behaves around recent trading ranges and how broader biotech sentiment evolves, as both could influence whether the current Buy profile is sustained or even strengthened over time. See full rankings of all B-rated Health Care stocks inside the Weiss Stock Screener.
--